QUOTE AND NEWS
Benzinga  Jun 19  Comment 
In a report published Friday, Cantor Fitzgerald analyst Irina Rivkind Koffler maintained a Hold rating on Ligand Pharmaceuticals Inc. (NASDAQ: LGND), while raising the price target from $86 to $93. While the stock appears to be “fairly...
Benzinga  Jun 15  Comment 
Analysts at FBR Capital downgraded EMC Corporation (NYSE: EMC) from Outperform to Market Perform. The price target for EMC has been lowered from $31.00 to $28.00. EMC shares closed at $27.07 on Friday. Analysts at Deutsche Bank downgraded Ligand...
newratings.com  Jun 12  Comment 
BASEL (dpa-AFX) - Ligand Pharmaceuticals Incorporated (LGND) announced that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and...
newratings.com  Jun 8  Comment 
THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN) has completed patient enrollment in the study, dubbed FOURIER outcomes trial, which is designed to evaluate if its investigational product Repatha in combination with statin therapy reduces the risk of...
GenEng News  May 14  Comment 
Immunotherapy enables a patient’s own immune system to battle cancerous target cells instead of either attacking the target cells directly or using whole-body approaches. Programmed death receptor-1 (PD-1), expressed on cell types including T...
GenEng News  May 14  Comment 
From small molecule and fragment-library screening to antibody-antigen target specificity, ligand screening is an increasingly important part of the drug discovery process. Ligand screening allows researchers to determine protein binding...
newratings.com  May 14  Comment 
PETAH TIKVA (dpa-AFX) - Teva Pharmaceutical Industries Ltd. (TEVA) announced the presentation of further data from its chronic migraine phase 2b study evaluating the efficacy and safety, versus placebo, of two doses of TEV-48125, an...
GenEng News  May 11  Comment 
Ligand Pharmaceuticals said today it acquired rights to more than 15 biologic development programs—along with their potential future milestone payments and royalties—from Selexis for $4 million cash. The agreement is based on more than 15...





You may also be interested in articles related to Ligand Pharmaceuticals (LGND):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki